AASLD: American Association for the Study of Liver Diseases
Home | Contact Us
About Us | News | JoinPatients | AASLD Foundation | Special Interest Groups | Committees
 

AASLD/EASL HCV Special Conference 
|

AASLD/EASL Special Conference on Hepatitis C
Sheraton New York Times Square Hotel
New York City, New York
Conference captures are available on LiverLearning®

Course Directors
Adrian M. Di Bisceglie, MD, FACP; Michael W. Fried, MD; Alessio Michele Aghemo, MD, PhD; and Darius Moradpour, MD

Two major developments—the recommendation for birth cohort screening and the recent approval of all-oral treatment regimens—are poised to change the landscape of HCV patient care. This special conference brought together a distinguished faculty from around the world to discuss the pathogenesis,
diagnosis, and treatment of the disease.

Attendees were presented with new therapeutic options that can cure the vast majority of patients. Attendees left the conference with insights on global epidemiology, barriers to care, and potential solutions to improve global access to therapy. 

Learning Objectives

  • To evaluate the impact of new strategies for screening of hepatitis C in the United States and abroad
  • To understand the changing global epidemiology of HCV infection
  • To recognize the strengths and limitations of recently approved therapeutic regimens
  • To evaluate new treatment regimens under development for HCV
  • To recognize barriers to care and identify potential solutions to improve global access to new HCV therapies

Target Audience
This was designed for hepatologists, gastroenterologists, NPs/PAs, epidemiologists, pharmacists and others with an interest in hepatitis C epidemiology and therapy.

 ‭(Hidden)‬ Custom List View Classes

This program is supported by independent medical educational grants from:

AbbVie
Bristol-Myers Squibb
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck

Salix Pharmaceuticals

No commercial entity was involved in decisions regarding the development of the program and selection of the speakers. In addition, there has not been any condition of purchase, use or recommendation of any products or services associated with the support of the AASLD/EASL HCV Special Conference.